Edgewise Therapeutics, Inc. financial data

Symbol
EWTX on Nasdaq
Location
Boulder, CO
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2377% % -13%
Debt-to-equity 5% % 9.8%
Return On Equity -32% % -19%
Return On Assets -30% % -19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 107,270,521 shares 2%
Common Stock, Shares, Outstanding 106,249,579 shares 12%
Entity Public Float $1,200,000,000 USD -14%
Common Stock, Value, Issued $10,000 USD 11%
Weighted Average Number of Shares Outstanding, Basic 102,930,744 shares 11%
Weighted Average Number of Shares Outstanding, Diluted 102,930,744 shares 11%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $151,389,000 USD 19%
General and Administrative Expense $40,017,000 USD 26%
Operating Income (Loss) $191,406,000 USD -21%
Net Income (Loss) Attributable to Parent $167,795,000 USD -25%
Earnings Per Share, Basic -1.63 USD/shares -12%
Earnings Per Share, Diluted -1.63 USD/shares -12%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $61,148,000 USD 47%
Assets, Current $543,385,000 USD 14%
Property, Plant and Equipment, Net $7,831,000 USD -18%
Operating Lease, Right-of-Use Asset $1,387,000 USD -12%
Other Assets, Noncurrent $695,000 USD
Assets $552,603,000 USD 14%
Accounts Payable, Current $6,006,000 USD 7.7%
Employee-related Liabilities, Current $12,430,000 USD 24%
Accrued Liabilities, Current $7,920,000 USD 9.6%
Liabilities, Current $27,370,000 USD 15%
Operating Lease, Liability, Noncurrent $2,976,000 USD -20%
Liabilities $30,346,000 USD 9.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $677,000 USD 61%
Retained Earnings (Accumulated Deficit) $546,371,000 USD -44%
Stockholders' Equity Attributable to Parent $522,257,000 USD 14%
Liabilities and Equity $552,603,000 USD 14%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $37,866,000 USD -32%
Net Cash Provided by (Used in) Financing Activities $2,223,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $43,898,000 USD
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 106,249,579 shares 12%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,255,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61,148,000 USD 47%
Deferred Tax Assets, Valuation Allowance $169,741,000 USD 52%
Deferred Tax Assets, Gross $170,228,000 USD 52%
Depreciation $2,084,000 USD 0.72%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $167,538,000 USD -26%
Property, Plant and Equipment, Gross $14,600,000 USD 2.9%
Operating Lease, Liability, Current $1,014,000 USD 1.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $1,067,941,000 USD 28%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $487,000 USD 15%
Share-based Payment Arrangement, Expense $34,752,000 USD 41%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%